It has been demonstrated that rosuvastatin exhibits immune-enhancing effects in certain settings, including an increase in NKT cell percentages and a reduction in TIM-3+ NK cells in chronic hepatitis B patients. Here, HAVCR2 is linked to chronic hepatitis B virus infection.